Loading...

RNA AVIDITY BIOSCIENCES INC US FDA Inspections 8-K Filing

VDTY

RN

AVIDITY BIOSCIENCES INC

(RNA)

2025 8-K

Summary

Summary

Merger Announcement

BLA Submission Update

Stock Offering Announcement

Stock Award Increase

Pre-Market Approval

Product Expansion

Earnings Releases

Office Expansion

Financial Results

Clinical Plans 2025

Cardiology Developments

Financial Results

Clinical Trial Update

FDA Approval Update

Earnings Reports

Investor Conferences

Annual Meeting Results

Underwriting Agreement

Amendment and Clinical Tria...

Appointment of Director

Earnings Reports

Investor Conferences

Private Placement

Resignation and Clinical Tr...

Clinical Trial Data

Bylaws Amendment

Agreement and Private Place...

Earnings Report

Clinical Study Data Present...

Earnings Reports

Annual Meeting Results

Clinical Hold Update

Earnings Reports

Presentation and Positive T...

Regulation FD Disclosure

Earnings Reports

Appointment of Directors an...

External Links:

On July 23, 2025, Avidity Biosciences announced that the FDA granted Breakthrough Therapy designation for its drug delpacibart zotadirsen (del-zota) aimed at treating Duchenne muscular dystrophy, with plans to submit a Biologics License Application by year-end 2025.

AI Assistant

AVIDITY BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.